SCHEMBL4074879

SCHEMBL4074879

CC(C)(C)c1cc(/C=C(/C#N)S(=O)(=O)c2ccc([N+](=O)[O-])cc2)cc(C(C)(C)C)c1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.48
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
MAPT P10636 5/20 0.48
HSD17B10 Q99714 4/20 0.48
HPGD P15428 4/20 0.48
ALDH1A1 P00352 4/20 0.48
ALOX15 P16050 3/20 0.48
CYP3A4 P08684 3/20 0.48
TSHR P16473 3/20 0.48
BLM P54132 3/20 0.48
LMNA P02545 3/20 0.48
GAA P10253 2/20 0.48
RGS12 O14924 2/20 0.48
GMNN O75496 2/20 0.48
TP53 P04637 2/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2C9 P11712 2/20 0.48
NFKB1 P19838 2/20 0.48
CYP2C19 P33261 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4073940 1.00 SMN1; SMN2 (0.48) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL4074884 1.00 SMN1; SMN2 (0.48) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL4071014 0.86 HPGD (0.52) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL4071011 0.86 HPGD (0.52) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL4070529 0.86 HPGD (0.57) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL4070166 0.86 HPGD (0.52) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL4070530 0.86 HPGD (0.57) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL4070167 0.86 HPGD (0.52) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL4073187 0.85 HPGD (0.51) SMN1; SMN2MEN1KMT2AMAPTHSD17B10
SCHEMBL3242402 0.85 KMT2A (0.51) SMN1; SMN2MEN1KMT2AMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1625112-B1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY HIGH POINT PHARMACEUTICALS LLC (US) 2009-07-22 EP claimed
JP-2007503453-A 2007-02-22 JP claimed
US-20060128662-A1 Novel compounds for treatment of obesity NOVO NORDISK A/S (DK) 2006-06-15 US claimed
EP-1625112-A1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2006-02-15 EP claimed
WO-2004101505-A1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2004-11-25 WO claimed
EP-1625112-B1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY HIGH POINT PHARMACEUTICALS LLC (US) 2009-07-22 EP disclosed
US-20060128662-A1 Novel compounds for treatment of obesity NOVO NORDISK A/S (DK) 2006-06-15 US disclosed
EP-1625112-A1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2006-02-15 EP disclosed
WO-2004101505-A1 NOVEL COMPOUNDS FOR TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128662-A1 Novel compounds for treatment of obesity GPR119, FABP4, HSD17B4 SMN1; SMN2 2597/4885MEN1 4794/4885KMT2A 2506/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.